Platform

GenVivo’s platform has been engineered to overcome key challenges of past vector-based immunotherapy approaches. Our non-replicating retrovector-based platform is designed to deliver therapeutic genes through systemic administration over multiple doses.

Our versatile platform allows for both an integrating approach for oncology applications, as well as a non-integrating option for multiple disease indications.